
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen is a market leader in biotechnology-based therapeutics, with a diverse portfolio of flagship drugs including red blood cell boosters and immune system boosters. The company's recent acquisition of Onyx Pharmaceuticals has bolstered their oncology portfolio, and the 2023 acquisition of Horizon has brought in several rare-disease drugs. In addition, Amgen's biosimilar portfolio continues to grow. The company's recent earnings report beat expectations and raised guidance, and upgrades to their core portfolio drivers have led to a revised price target and outlook.
Bears say
Amgen is facing challenges with patent expirations and potential biosimilar competition, introducing uncertainty into its revenue stream. The upcoming catalysts, while promising, are several years away and present risks due to the long timeline and potential for any setbacks. This, combined with a high discount rate and low terminal growth rate in our DCF analysis, leads to our negative outlook for the stock.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares